Boston BioLife, an organization founded in July 2015 to help physicians and scientists understand emerging developments in regenerative and translational medicine, will co-present the Translational Longevity Summit from October 7-11, 2026, at Harvard’s Enterprise Research Campus in Boston. The five-day event, presented with the Healthspan Action Coalition as part of Boston Longevity Week, will convene leaders from science, medicine, technology, patient advocacy, policy and investment to examine how promising discoveries can be responsibly evaluated, translated and advanced toward meaningful clinical application.
The summit marks a significant expansion of Boston BioLife’s founding mission. Founder Joseph P. Krieger started the organization after recognizing that successful clinical adoption of new medical technologies required more than introducing a device or discovery. Healthcare professionals needed to understand the underlying science, appropriate applications, limitations, regulatory considerations and patient-safety implications. “When I founded Boston BioLife, the goal was to help physicians understand emerging science and determine how it could responsibly contribute to better patient care,” Krieger said. “Eleven years later, this summit gives us the opportunity to expand that conversation across the entire translational ecosystem—from researchers and clinicians to patients, policymakers and investors.”
Krieger’s path to Boston BioLife began with an education in biochemistry and a career in medical-device technology and physician training. While creating educational programs around radiofrequency ablation and other medical technologies, he saw that clinical adoption required a deeper understanding of the science and its practical implications. In a 2016 BioInformant interview, he described the organization’s purpose as facilitating the understanding of life-science technologies in clinical medicine and helping move innovation from “bench to bedside.” He emphasized accurate research, regulatory awareness and patient safety—principles that continue to guide Boston BioLife today.
The Translational Longevity Summit extends that work into the rapidly evolving field of longevity. Discussions will explore aging, healthspan, regenerative medicine, personalized care and the scientific and practical challenges involved in moving new discoveries from research environments into responsible real-world use. The summit will also emphasize cross-sector collaboration, with researchers, physicians, industry leaders, technology developers, patient advocates, policy voices and investors each playing a role in determining how emerging science is studied, funded, regulated, understood and ultimately made accessible. Patient participation will be an important part of that conversation, as people living with illness and age-related conditions bring essential perspectives on urgency, daily function, treatment burden and unmet needs.
“Translation does not happen within a single laboratory, company or medical practice,” Krieger added. “It requires researchers, clinicians, patients, regulators, advocates and responsible industry partners to ask better questions together. That is the community we are bringing together in Boston.” For a Massachusetts native who built his career near Boston’s medical, academic and scientific institutions, holding the summit at Harvard’s Enterprise Research Campus carries particular significance. The location brings Boston BioLife’s original educational mission into an environment created to encourage research, innovation and collaboration.
Eleven years after its founding, Boston BioLife’s purpose remains consistent: to help the healthcare community understand emerging science and evaluate its potential relevance to patient care. In October, that enduring mission will bring a broader community together in Boston to address one of longevity medicine’s most important challenges: translating scientific promise into responsible, measurable progress. The summit’s focus on collaboration and patient involvement underscores the growing recognition that advancing longevity science requires not only scientific breakthroughs but also careful consideration of regulatory, ethical and practical factors to ensure innovations reach patients safely and effectively.
